-
2022-501308-90-00
4
2023-05-24
Molecularly selected and resectable primary colorectal cancer
-
2024-512878-98-00
9
2023-05-16
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative
Breas
-
2022-502051-56-00
5
2023-04-28
H3 K27M-mutant diffuse glioma
-
2023-505189-26-00
9
2023-03-28
Advanced esophageal squamous cell carcinoma
-
2022-501238-52-00
10
2023-03-23
Heart failure due to systemic left ventricular systolic dysfunction
-
2024-514666-39-00
4
2023-03-16
Extensive-Stage Small-Cell Lung Cancer (ES SCLC)
-
2022-501894-37-00
4
2023-03-02
prostate cancer
-
2024-520119-41-00
4
2023-01-15
Previously untreated patients with diagnosis of HCL
-
2022-501090-39-00
5
2022-12-14
Biliary Atresia
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2024-514266-39-00
7
2022-11-03
Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors wit
-
2023-510240-20-00
4
2022-10-05
Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2023-504660-41-00
4
2022-07-11
Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
-
2024-511635-94-00
4
2022-07-11
Relapsed or Refractory Plasmablastic lymphoma
-
2023-508852-21-00
4
2022-06-10
Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
-
2024-513412-10-00
9
2022-05-11
Anaplastic Large Cell Lymphoma (ALCL)
-
2024-515681-14-00
4
2022-05-02
Stage II (pT4)/III colorectal cancer with positive circulating tumor D
-
2024-511793-71-00
7
2022-02-28
Advanced ROS1-positive NSCLC and other advanced ROS1-positive solid tu
-
2024-514687-33-00
4
2021-12-21
Previously Untreated Chronic Lymphophatic Leukaemia
-
2023-505497-14-00
4
2021-12-09
Proteinuric glomerular diseases including:
•Focal segmental glomerulo
-
2024-513931-26-00
4
2021-12-01
locally advanced rectal cancer (LARC)
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre